Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease

Abstract Background Metabolic dysfunction associated steatotic liver disease (MASLD) is prevalent in up to 60% of patients with type 2 diabetes mellitus (T2DM). T2DM accelerates the risk of hepatic fibrosis and hepatocellular carcinoma in patients with MASLD. Our goal in this study was to identify p...

Description complète

Détails bibliographiques

Auteurs principaux:	Ahmed Ebeid, Fatma Mokhtar, Valeria Martinez-Lebron, Susie Park, Seta Degann, Jeremy Payano, Zahid Vahora, Stephen Gray, Lynt Johnson, Diala El-Maouche, Ameer Abutaleb
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-02-01
Collection:	BMC Endocrine Disorders
Sujets:	Metabolic dysfunction associated steatotic liver disease (MASLD) MASH Fibrosis scoring systems Non-invasive tests Advanced liver fibrosis
Accès en ligne:	https://doi.org/10.1186/s12902-025-01881-9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!